Impact of peroxide content in excipients and antioxidants on famotidine oxidative stability

1 A. S. Taha, N. Hudson, C. J. Hawkey, A. J. Swannell, P. N. Trye, J. Cottrell, S. G. Mann, T. J. Simon, R. D. Sturrock and R. I. Russell, Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs, N. Engl. J. Med. 334(22) (1996) 1435–1439; https://doi.org/10.1056/NEJM199605303342204 Search in Google Scholar

2 A. S. Taha, C. McCloskey, R. Prasad and V. Bezlyak, Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial, Lancet 374(9684) (2009) 119–125; https://doi.org/10.1016/S0140-6736(09)61246-0 Search in Google Scholar

3 S. Bajaj, D. Singla and N. Sakhuja, Stability testing of pharmaceutical products, J. Appl. Pharm. Sci. 2(3) (2012) 129–138; https://doi.org/10.7324/JAPS.2012.2322 Search in Google Scholar

4 M. Bakshi and S. Singh, Development of validated stability-indicating assay methods—critical review, J. Pharm. Biomed. Anal. 28(6) (2002) 1011–1040; https://doi.org/10.1016/S0731-7085(02)00047-X Search in Google Scholar

5 M. Blessy, R. D. Patel, P. N. Prajapati and Y. K. Agrawal, Development of forced degradation and stability indicating studies of drugs – A review, J. Pharm. Anal. 4(3) (2014) 159–165; https://doi.org/10.1016/j.jpha.2013.09.003 Search in Google Scholar

6 M. Dong, K. Huynh-Ba and J. Ayers, Development of stability-indicating analytical procedures by HPLC: An overview and best practices, Pharm. Technol. 38(8) (2020) 440–456. Search in Google Scholar

7 A. Roy, J. Henry, A. Wilken and L. Collazo-Malave, Current practices and considerations for a stability-indicating method in pharmaceutical analysis, Pharm. Technol. 32 (2014) 568–575. Search in Google Scholar

8 J. M. Campbell, C. Foti, C. Wang, N. Adams, L. R. Allain, G. Araujo, R. Azevedo, J. R. Franca, S. R. Hicks, S. Hostyn, P. J. Jansen, D. Kotoni, A. Kuemmell, S. Marden, G. Rullo, A. C. O. Santos, G. W. Sluggett, T. Zelesky and S. W. Baertschi, Assessing the relevance of solution phase stress testing of solid dosage form drug products: A cross-industry benchmarking study, J. Pharm. Sci. 111 (2022) 298–305; https://doi.org/10.1016/j.xphs.2021.06.012 Search in Google Scholar

9 S. Singh, M. Junwal, G. Modhe, H. Tiwari, M. Kurmi, N. Parashar and P. Sidduri, Forced degradation studies to assess the stability of drugs and products, Trends Anal. Chem. 49 (2013) 71–88; https://doi.org/10.1016/j.trac.2013.05.006 Search in Google Scholar

10 V. Dave, R. Haware, N. Sangave, M. Sayles and M. Popielarczyk, Drug-excipient compatibility studies in formulation development: Current trends and techniques, AAPS Formul. Des. Dev. Sect. Newsl. (2015) 9–15. Search in Google Scholar

11 G. Bruni, L. Amici, V. Berbenni, A. Marini and A. Orlandi, Drug-excipient compatibility studies: Search of interaction indicators, J. Therm. Anal. Calorim. 68 (2002) 561–573; https://doi.org/10.1023/a:1016052121973 Search in Google Scholar

12 R. Chadha and S. Bhandari, Drug-excipient compatibility screening – Role of thermoanalytical and spectroscopic techniques, J. Pharm. Biomed. Anal. 87 (2014) 82–97; https://doi.org/10.1016/j.jpba.2013.06.016 Search in Google Scholar

13 A. Gabrič, Ž. Hodnik and S. Pajk, Oxidation of drugs during drug product development: Problems and solutions, Pharmaceutics 14(2) (2022) Article ID 325 (19 pages); https://doi.org/10.3390/pharmaceutics14020325 Search in Google Scholar

14 A. S. Narang, V. M. Rao and D. S. Desai, Effect of antioxidants and silicates on peroxides in povi-done, J. Pharm. Sci. 101(1) (2012) 127–139; https://doi.org/10.1002/jps.22729 Search in Google Scholar

15 W. R. Wasylaschuk, P. A. Harmon, G. Wagner, A. B. Harman, A. C. Templeton, H. Xu and R. A. Reed, Evaluation of hydroperoxides in common pharmaceutical excipients, J. Pharm. Sci. 96(1) (2007) 106–116; https://doi.org/10.1002/jps.20726 Search in Google Scholar

16 Y. Wu, J. Levons, A. S. Narang, K. Raghavan and V. M. Rao, Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility, AAPS PharmSciTech 12 (2011) 1248–1263; https://doi.org/10.1208/s12249-011-9677-z Search in Google Scholar